Imagine if your gut could act like a second set of lungs. Instead of using heavy breathing machines to get rid of waste gas in the blood, this liquid is taken by mouth or rectum to soak up CO2 from the inside. It then carries that gas out of the body naturally, letting the tired lungs finally rest.
Patients with COPD and acute lung failure suffer from hypercapnia, which currently requires invasive mechanical ventilation. This significantly lowers quality of life and creates a high socioeconomic burden.
A medical device consisting of a therapeutic liquid (RESPILIQ™) and a pilot production plant for its manufacture.
If you are a medical device provider dealing with the limitations of invasive ventilation—this project developed a liquid-based CO2 absorber that allows the gut to act as a respiratory organ. This reduces the need for intensive mechanical ventilation for patients with COPD.
If you are a pharma company dealing with the high socioeconomic burden of chronic lung diseases—this project developed a therapeutic liquid that binds CO2 in the intestinal fluid. It provides a less invasive alternative to extracorporeal blood filtration systems.
If you are a clinic dealing with 1.8M people in Europe suffering from hypercapnia—this project developed an oral or rectal administration method to lower blood CO2. This improves the quality of life for patients who struggle with home-based ventilation.
Based on available project data, specific pricing or cost-per-unit information is not provided.
The project has developed a pilot plant to support the production and testing of the liquid therapy.
Based on available project data, specific patent numbers or licensing terms are not listed, though the product is branded as RESPILIQ™.
The product is classified as a medical device and must demonstrate safety and efficacy, which has been initiated through preclinical studies.
The project period runs from 2024-05-01 to 2026-04-30, suggesting the development and validation phase is currently active.
The project is led by a single German SME, BIOMEDICAL GMBH, which holds 100% of the industry ratio. This lean structure suggests a highly focused development path with direct control over the IP and a fast transition from the pilot plant to clinical application.
Contact BIOMEDICAL GMBH in Germany
Contact us to explore licensing opportunities for this enteral CO2 absorption technology.
